MedTrace Logo

Effect of Honey For CIN II

NCT06219018 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-18

No results posted yet for this study

Summary

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.

Conditions

  • Cervical Intraepithelial Neoplasia-II
  • High Risk Human Papillomavirus

Interventions

DRUG

Medical grade honey formulation (MGH) (L-Mesitran®)

Daily application of 5 grams (with applicator) for the first 3 months, followed by weekly application of 5 grams for the following 3 months.

Sponsors & Collaborators

  • Zuyderland Medisch Centrum

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2026-12-01
Completion
2027-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06219018 on ClinicalTrials.gov